Company Interpace Biosciences, Inc.

IDXG

US46062X3035

Managed Healthcare

Market Closed - OTC Markets Other stock markets 03:36:01 2024-04-16 pm EDT			5-day change	1st Jan Change
1.47 ^USD	0.00%		+8.89%	+36.11%

Mar. 07	Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	MT
Mar. 07	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Business Summary

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

Number of employees: 108

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Diagnostic Clinical Services 100.0 %	32	100.0 %	40	100.0 %	+26.31%

Sales per region

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	32	100.0 %	40	100.0 %	+26.31%

Managers

Managers	Title	Age	Since
Thomas Burnell CEO	Chief Executive Officer	62	20-11-30
Christopher McCarthy DFI	Director of Finance/CFO	32	19-05-31
Nicole Massoll CTO	Chief Tech/Sci/R&D Officer	-	-
Sydney D. Finkelstein CTO	Chief Tech/Sci/R&D Officer	-	-
Jody Campbell PRN	Corporate Officer/Principal	-	-

Members of the board

Members of the board	Title	Age	Since
Vijay Aggarwal BRD	Director/Board Member	75	22-01-31
Joseph Keegan BRD	Director/Board Member	71	15-12-31
Stephen Sullivan BRD	Director/Board Member	77	04-08-31
Fortunato Rocca BRD	Director/Board Member	62	20-01-21
Thomas Burnell CEO	Chief Executive Officer	62	20-11-30

Share class

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	47,000	0	0	72.42 %
Stock B	1	4,472,442	3,239,074 ( 72.42 %)	96,044 ( 2.147 %)

Shareholders

Name	Equities	%	Valuation
Peter Kamin 18.09 %	781,956	18.09 %	1 M $
Douglas Mark Singer 5.785 %	250,000	5.785 %	375 000 $
Thomas Burnell 1.308 %	56,521	1.308 %	84 782 $
Christopher McCarthy 1.056 %	45,644	1.056 %	68 466 $
Robert Gorman 0.4341 %	18,759	0.4341 %	28 139 $
Stephen Sullivan 0.0569 %	2,459	0.0569 %	3 689 $
Joseph Keegan 0.0407 %	1,757	0.0407 %	2 636 $
SciVest Alternative Strategies, Inc. 0.003748 %	162	0.003748 %	243 $
NWD Investments 0.001851 %	80	0.001851 %	120 $
Merrill Lynch Investment Managers, Inc. 0.000787 %	34	0.000787 %	51 $